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Background: To evaluate the effects of contrast agents containing increasing concentrations of iodine on the renal
oxygenation level determined by blood oxygenation level dependent (BOLD) magnetic resonance imaging (MRI) in
a rabbit model of diabetic nephropathy.
Methods: BOLD-MRI was performed using saline or iodinated (I) contrast agents (200, 240, 300, 350 and 400 mg I/mL)
at 1, 24, 48, and 72 h after experimentally inducing type 2 diabetic nephropathy in rabbits. Differences in renal
oxygenation levels between type 1 and type 2 diabetic nephropathy were also assessed by BOLD-MRI after injecting
400 mg I/mL of contrast agent.
Results: Contrast agents increased the R2* values of the renal cortex, outer medulla, and inner medulla to the
maximum levels at 24 h. The R2* values then decreased to their lowest levels at 72 h. The R2* was highest following
injection of 400 mg I/mL, especially in the outer medulla. The R2* values were not significantly different between types
1 and 2 diabetic nephropathy.
Conclusions: Iodinated contrast agents had the greatest influence on renal outer medulla oxygenation level at 24 h
in type 2 diabetic nephropathy, with the greatest effects observed at the 400 mg I/mL dose level. There were no
differences in BOLD-MRI values between type 1 and type 2 diabetic nephropathy after administering the contrast agent
at 400 mg I/mL.
Keywords: Blood oxygenation level dependent magnetic resonance imaging, Diabetic nephropathy, Iodinated
contrast agent, Rabbit, PimonidazoleBackground
The development of an international economy and im-
provements in living standards have led to progressive
increases in the morbidity and prevalence of diabetes
mellitus, such that diabetes mellitus is now a major pub-
lic health concern. Worldwide, 284 million people were
estimated to have diabetes in 2010, representing 6.4% of* Correspondence: zhongguoyidarenke@163.com; zhongguoyidaxuke@126.com
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unless otherwise stated.the total population. Furthermore, it was predicted that
439 million individuals worldwide, 7.7% of the total
population, will have diabetes mellitus in 2030 [1].
Diabetic nephropathy affects 15–25% of patients with
type 1 diabetes and 30–40% of patients with type 2 dia-
betes [2]. Iodinated contrast agents are mainly metabo-
lized in the kidneys. Contrast agents sometimes cause
hypoxia in the kidney—a deficiency of oxygenation and
the primary feature of progressive chronic kidney disease
[3-5]. According to the studies by Pakfetrat et al. [6] and
Toprak and Cirit [7], renal insufficiency and chronic kid-
ney disease are major risk factors for contrast-inducedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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betes. CIN is defined as an increase in the serum cre-
atinine level of ≥0.5 mg/dL or an increase of ≥25% above
baseline [8]. Generally, CIN is usually transient because
the serum creatinine starts to rise within 24–48 h after
exposure and reaches its peak value within 3–5 days
after administration of the contrast agent, and subse-
quently declines [9]. Therefore, early detection of CIN is
challenging.
Functional magnetic resonance imaging (MRI), espe-
cially blood oxygenation level dependent (BOLD) MRI,
can facilitate detailed noninvasive assessment of renal
function. This technique has been used to study the ef-
fects of iodinated contrast agents on the kidney in initial
feasibility studies in humans [10,11]. Tissue oxygenation
bioavailability can be evaluated in terms of the R2*
values. The increase of transverse relaxation rate R2*
values reflect a poor oxygenation content in tissue [12].
Prasad [13] reported that the baseline R2* values in the
renal medulla of spontaneously hypertensive rats were
significantly greater than those of Wistar–Kyoto rats,
implying lower oxygenation in spontaneously hyperten-
sive rats. In the present study, we used BOLD-MRI to
examine the effects of iodine-containing contrast agents
on renal oxygenation in a New Zealand white rabbit
model of diabetic nephropathy.
Methods
Experimental subjects
All animal procedures were approved by the ethics com-
mittee of China Medical University and complied with
guidance for the Care and Use of Laboratory Animals
(National Research Council, National Academy Press,
Washington, DC, 1996). Ninety-six male New Zealand
rabbits (6–8 months old; weighing 2.0–3.0 kg) were ob-
tained from the Animal Department of China Medical
University. All procedures were performed under general
anesthesia. Food and water was withheld for 6 h during
the experiments. The rabbits were allocated to three ex-
perimental groups (control, type 1 diabetic nephropathy,
and type 2 diabetic nephropathy).
Control group
The control group comprised 12 normal rabbits that
were injected with physiological saline only.
Type 1 diabetic nephropathy
This group included 12 rabbits, which were injected
with 150 mg/kg alloxan monohydrate (Sigma Chemical
Co., St, Louis, MO, USA) dissolved in physiological sa-
line (5 g/100 mL) via a 22 G venous indwelling needle
through the auricular vein. Because alloxan damages islet
cells, severe hypoglycemia was expected to occur within
24–48 h after injection. Therefore, the rabbits had freeaccess to 10% glucose water for 48 h after injection. The
development of type 1 diabetes mellitus was considered
successful if the blood glucose was ≥16 mmol/L [14] at
2–3 weeks after injection. The rabbits were fed a conven-
tional diet for 12 weeks. After 12 weeks, blood glucose
levels and the extent of kidney damage were assessed
using blood and urine biochemical examinations.
Type 2 diabetic nephropathy
Type 2 diabetic nephropathy was induced in 72 rabbits by
providing them a high-glucose and high-fat diet (5 g sac-
charose and 1 g cholesterol per 100 g of food; cholesterol
was obtained from Sigma Chemical Co.). Granulated sugar
with a glycemic index of >100 was dissolved in drinking
water to a dilution of 1 g/mL. After 8 weeks, blood sam-
ples were obtained from the auricular vein for biochemical
examinations, including fasting blood glucose, serum
lipids, and high-sensitivity C reactive protein. Insulin re-
sistance was considered to be present if these indices had
increased from baseline [15]. After 12 weeks, blood glu-
cose levels and the extent of kidney damage were assessed
using blood and urine biochemical examinations.
Preparation of contrast agents
Five iodinated (I) contrast agents were obtained from
the GE Pharmaceutical Shanghai Co. Ltd. (Shanghai,
China) and were used in the experiment: 200 mg I/mL
(viscosity: 0.20 NS/M2 at 37°C; osmolality: 413 mOsm/
kg H2O); 240 mg I/mL (viscosity: 0.33 NS/M
2 at 37°C;
osmolality: 510 mOsm/kg H2O); 300 mg I/mL (viscosity:
0.61 NS/M2 at 37°C; osmolality: 640 mOsm/kg H2O);
350 mg I/mL (viscosity: 1.06 NS/M2 at 37°C; osmolality:
780 mOsm/kg H2O); and 400 mg I/mL (viscosity: 1.26
NS/M2 at 37°C; osmolality: 920 mOsm/kg H2O).
Experimental protocols
Protocol 1
Control rabbits and rabbits with experimentally induced
type 2 diabetic nephropathy were divided into seven
groups of 12 rabbits each. The control group and the posi-
tive control group (rabbits with type 2 diabetic nephropa-
thy) were injected with physiological saline. At the same
time, the other five groups of rabbits with type 2 diabetic
nephropathy were injected with either 200, 240, 300, 350,
or 400 mg I/mL of contrast agent (1 g iodine/kg body
weight) [16]. BOLD-MRI was performed 1, 24, 48, and
72 h after injecting the contrast agent. The R2* values
were determined for the renal cortex, outer medulla, and
inner medulla, and were compared among the study
groups at the same times.
Protocol 2
We selected the iodinated contrast agent that had the
largest effect on the renal oxygenation level in Protocol
Table 1 Body weights of rabbits in each group




Baseline (kg) 2.60 ± 0.52 2.67 ± 0.42 2.72 ± 0.51
After 2 weeks (kg) 2.62 ± 0.43 2.79 ± 0.43 2.89 ± 0.43
After 12 weeks (kg) 2.64 ± 0.48 3.12 ± 0.70 3.18 ± 0.79
Abbreviations: DN diabetic nephropathy.
Values are means ± standard deviation.
There were no significant differences in body weight among the three groups
at any time.








Kidney weight (g) 9.6 ± 1.42 10.07 ± 2.29* 10.51 ± 2.38*
Blood glucose (mmol/L) 4.77 ± 1.13 23.37 ± 6.72* 22.66 ± 5.00*
SCr (μmol/L) 56.24 ± 11.53 169.00 ± 12.08* 155.20 ± 13.27*
BUN (mmol/L) 4.28 ± 0.53 9.82 ± 0.76* 9.88 ± 0.69*
Urinary microalbumin
(mg/L)
6.51 ± 1.38 21.71 ± 3.72* 21.39 ± 3.17*
Fasting insulin (μIU/mL) 7.61 ± 2.31 1.25 ± 1.37* 32.65 ± 2.56*
GAD-Ab† − + −
IAA† − + −
Abbreviations: DN diabetic nephropathy, SCr serum creatinine, BUN blood urea
nitrogen, GAD-Ab glutamic acid decarboxylase autoantibody, IAA
insulin autoantibody.
Normal ranges: blood glucose, 3.61–6.11 mmol/L; SCr, 44–133 μmol/L; BUN,
3.2–7.1 mmol/L; urinary microalbumin, <10 mg/L; fasting insulin,
5.8–18.6 μIU/mL.
Values are means ± standard deviation.
*P < 0.05 vs. control group.
There were no significant difference between types 1 and 2 diabetic
nephropathy in terms of blood glucose, SCr, BUN, and urinary
microalbumin results.
†Positivity for GAD-Ab and IAA is indicative of type 1 diabetes.
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diabetic nephropathy and control rabbits were divided
into groups of 12 rabbits each. BOLD-MRI was per-
formed 1, 24, 48, and 72 h after injecting the iodinated
contrast agent. The effects of the contrast agent on the
R2* values of the renal cortex, outer medulla, and inner




All MRI examinations were carried out using a 3.0 T Twin
Speed whole-body MR scanner (General Electric Medical
Systems, Milwaukee, WI, USA). A tightly fixed standard
knee matrix coil with 16 independent receiver elements
was used to enhance signal reception. After anesthesia, all
of the rabbits were scanned in a supine position, starting
at the head. The contrast agents were warmed to 37°C
and were manually injected via a 22 G venous indwelling
needle through the rabbit’s auricular vein. BOLD scanning
was performed using a multiple-echo spoiled gradient
recalled echo protocol through the center of the kidney
and the following parameters, as previously described
[17]: repetition time = 101.5 ms; echo time = 6.3–32 ms;
flip angle = 30°; bandwidth = 31.25 kHz; matrix = 160 × 160;
field of view = 18 cm× 18 cm; section thickness = 4 mm;
and section number = 6.
Data analysis
ADVANCE 4.4 Workstation software (General Electric
Medical Systems) was used to analyze the BOLD images.
The R2* values were determined by placing a region of
interest (ROI) marker on the upper pole, middle, and in-
ferior pole of the kidney using coronal BOLD images.
Six ROI markers were placed in the renal cortex, outer
medulla, and inner medulla of each kidney and 36 ROI
markers were simultaneously placed on both kidneys in
each rabbit. The ROI was set to 5 mm3 and was placed
to avoid the fatty tissues of the renal sinus and blood
vessels. To prevent significant bias associated with meas-
urement variability, each image was measured independ-
ently in triplicate by three professional radiologists, each
with over 5 years’ experience.
Pathology and immunohistochemistry
Three rabbits from each group were killed at specific time
points (1, 24, 48, and 72 h). The kidneys were placed in
formaldehyde solution for 24 h and then prepared for
tissue dehydration, paraffin embedding, and sectioning,
followed by hematoxylin and eosin staining. At a magnifi-
cation of 400×, tissue injury was assessed using the follow-
ing injury scoring criteria: 0–1.0, damage is limited to the
glomerular structure; 1.1–2.0, damage has extended to thetubule cells; and 2.1–3.0, damage includes expansion and
congestion of the capillaries.
Pimonidazole (Natural Pharmacia, Burlington, MA,
USA) staining was used as an independent method to as-
sess the extent of hypoxia in the renal tissues of the
experimental groups. Renal hypoxia was evaluated semi-
quantitatively based on the extent of pimonidazole stain-
ing of tubules in the cortex and medulla. Using five
randomly selected images for each time point, the inten-
sity of pimonidazole staining was assessed at a magnifica-
tion of 200× according to the following criteria: 0–1.0, no
staining; 1.1–2.0, moderate; and 2.1–3.0, strong staining.
Pimonidazole (60 mg/kg) was administered via intraper-
itoneal injection and the rabbits were killed 1.5 h later.
Perfusion-fixed kidneys (3% paraformaldehyde) were cut
into 4-μm-thick sections and were processed for immuno-
staining with an EnVision System horseradish peroxidase
kit (Dako, Carpinteria, CA, USA) according to the ma-
nufacturer’s instructions. Briefly, after deparaffinization,
Table 3 R2* values in the control group and in the type 2 diabetic nephropathy groups injected with iodinated
contrast agents
Kidney tissue Treatment 1 h 24 h 48 h 72 h
Cortex CG 19.0 ± 2.3 18.9 ± 2.1 19.2 ± 2.2 18.9 ± 2.7
DN PC 24.5 ± 3.6* 24.5 ± 4.3* 24.7 ± 4.5* 25.4 ± 3.7*
DN 200 31.1 ± 3.2* 31.3 ± 4.9* 30.9 ± 3.6* 28.9 ± 4.3*
DN 240 33.3 ± 4.6* 34.8 ± 4.8* 34.0 ± 3.1* 33.5 ± 7.9*
DN 300 41.7 ± 5.1* 41.9 ± 3.4* 40.1 ± 5.5* 39.2 ± 4.0*
DN 350 46.7 ± 5.2* 50.2 ± 5.8* 48.9 ± 5.7* 43.7 ± 6.0*
DN 400 50.1 ± 5.6* 57.6 ± 5.3* 53.9 ± 6.1* 47.4 ± 5.5*
Outer medulla CG 20 ± 4.2 22.7 ± 4.8 22.4 ± 5.4 21.6 ± 5.1
DN PC 29.9 ± 4.4* 30.7 ± 5.1* 28.2 ± 5.8* 29.5 ± 5.4*
DN 200 38.1 ± 4.6* 40.1 ± 6.2* 37.5 ± 4.8* 33.8 ± 5.8*
DN 240 42.3 ± 3.5* 43.3 ± 5.7* 40.3 ± 4.2* 37.3 ± 3.5*
DN 300 53.4 ± 5.2* 57.9 ± 5.6* 48.8 ± 4.8* 45.4 ± 5.2*
DN 350 60.6 ± 6.3* 72.4 ± 5.7* 62.9 ± 5.5* 56.5 ± 5.3*
DN 400 67.6 ± 5.6* 80.4 ± 6.3* 74.7 ± 6.1* 67.7 ± 5.8*
Inner medulla CG 20.2 ± 2.4 20.0 ± 3.6 21.8 ± 2.7 20.5 ± 3.2
DN PC 22.7 ± 4.7* 24.5 ± 3.8* 24.3 ± 4.0* 22.9 ± 3.4*
DN 200 27.2 ± 3.3* 30.6 ± 4.0* 26.2 ± 2.7* 25.0 ± 3.5*
DN 240 30.4 ± 3.8* 33.6 ± 5.8* 31.9 ± 4.2* 29.9 ± 5.2*
DN 300 42.8 ± 5.2* 44.2 ± 5.0* 38.8 ± 4.9* 32.7 ± 4.8*
DN 350 49.2 ± 5.7* 50.2 ± 4.8* 47.3 ± 5.8* 39.4 ± 5.1*
DN 400 55.2 ± 5.4* 57.2 ± 5.3* 55.3 ± 6.3* 46.4 ± 5.7*
Abbreviations: CG control group, DN diabetic nephropathy, PC positive control; 200 200 mg I/mL contrast agent; 240 240 mg I/mL contrast agent, 300 300 mgI/mL
contrast agent, 350 350 mg I/mL contrast agent, 400 400 mg I/mL contrast agent.
The control group and the DN PC group were injected with physiological saline/.
Values are means ± standard deviation.
*P < 0.05 vs. the control group.
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were incubated with protein blocking solution for 20 min.
The sections were sequentially incubated with a specific
rabbit anti-pimonidazole antibody diluted 1:100 (Natural
Pharmacia Inc.) for 1 h, were and labeled with a poly-
mer horseradish peroxidase-conjugated anti-rabbit sec-
ondary antibody. Pimonidazole staining was visualized
using 3,3′-diaminobenzidine, followed by counterstain-
ing with hematoxylin. Renal hypoxia was evaluatedFigure 1 R2* values of the renal cortex (A), outer medulla (B), and inn
physiological saline, the R2* values increased at 1 h and reached their peak
groups injected with iodinated contrast agents. The greatest changes occusemi-quantitatively based on the extent of pimonidazole
staining of tubules in the cortex and medulla.
Statistical analysis
All data are presented as the mean ± standard deviation.
Multi-level analysis of variance was used to compare the
R2* values among the contrast agent-injected groups and
the control group at the same time points. Rank sum
tests were used to obtain non-normal distributions orer medulla (C). Compared with the control group injected with
s at 24 h and then decreased to the lowest values at 72 h in the five
rred in the 400 mg I/mL group.
Table 4 R2* values after an injection of 400 mg I/mL
contrast agent in the control group, and type 1 and type
2 diabetic nephropathy groups
1 h 24 h 48 h 72 h
Cortex
CG 39.7 ± 5.4 44.2 ± 5.5 43.2 ± 4.7 37.8 ± 5.7
Type 1 DN 50.3 ± 5.5* 57.1 ± 5.2* 54.2 ± 5.9* 46.2 ± 6.5*
Type 2 DN 50.1 ± 5.6* 57.6 ± 5.3* 53.9 ± 6.1* 47.4 ± 5.5*
Outer medulla
CG 52.7 ± 5.1 60.4 ± 6.2 53.6 ± 6.7 49.5 ± 6.2
Type 1 DN 68.6 ± 5.9* 80.3 ± 5.6* 76.7 ± 5.5* 68.1 ± 5.9*
Type 2 DN 67.6 ± 5.6* 80.4 ± 6.3* 74.7 ± 6.1* 67.7 ± 5.8*
Inner medulla
CG 44.4 ± 5.7 49.9 ± 5.6 47.5 ± 5.6 39.9 ± 6.2
Type 1 DN 54.7 ± 6.1* 57.6 ± 5.4* 54.1 ± 6.6* 45.7 ± 6.1*
Type 2 DN 55.2 ± 5.4* 57.2 ± 5.3* 55.3 ± 6.3* 46.4 ± 5.7*
Abbreviations: CG control group; DN diabetic nephropathy.
Values are means ± standard deviation.
*P < 0.05 vs. the control group.
There were no significant differences in the R2* values between the type 1
and type 2 diabetic nephropathy groups in the same renal compartment at
the same time.
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sidered statistically significant. Statistical analyses were
performed using SPSS software version 17.0 (SPSS Inc.,
Chicago, IL, USA).Results
The bodyweights of rabbits in all of the study groups
were similar during the study (Table 1). Types 1 and 2
diabetes were successfully induced and rabbits could be
differentiated based on their fasting insulin, glutamic
acid decarboxylase autoantibody, and insulin autoanti-
body levels (Table 2). There were no differences in blood
glucose, serum creatinine, blood urea nitrogen, and urin-
ary microalbumin levels between rabbits with type 1 and
type 2 diabetic nephropathy (Table 2). BOLD imagesFigure 2 BOLD images obtained using 400 mg I/mL of contrast agent
with saline. (C–F) Type 2 diabetic nephropathy group injected with 400 mg
intensities on the R2* map indicate lower oxygenation of the underlying ti
greater than that in the cortex and inner medulla, which implies lower oxywere successfully acquired without dropouts and all
protocol data were successfully obtained.Protocol 1
The R2* values were similar among the renal cortex,
outer medulla, and inner medulla (Table 3, Figure 1).
Compared with the negative control group, which was
injected with physiological saline, the R2* values in-
creased at 1 h in the experimental groups, reaching their
peak values at 24 h. The R2* values then declined, reach-
ing their lowest values at 72 h. The R2* values were con-
sistently higher in the outer medulla than in the cortex,
and increased to a peak by 24 h. Among the five dose-
groups, 400 mg I/mL elicited the greatest difference in
the R2* value of the outer medulla at 24 h compared
with the control group (P = 0.001). These results indicate
that 400 mg I/mL had the greatest effect on the renal
outer medulla at 24 h. The R2* values for each part of
the kidney decreased to their lowest values by 72 h. In
addition, 400 mg I/mL elicited the greatest effect on the
R2* value of the outer medulla at 72 h compared with
the control group (P = 0.003), which indicates that there
was considerable damage to the renal outer medulla at
72 h after injecting 400 mg I/mL of the contrast agent.Protocol 2
Based on the results of Protocol 1, we used the 400 mg
I/mL dose of the contrast agent in Protocol 2. Rabbits
with experimentally induced type 1 or type 2 diabetic
nephropathy and control rabbits underwent BOLD MRI
at 1–72 h after injecting the contrast agent. The R2*
values increased significantly in rabbits with diabetic ne-
phropathy group compared with the control group.
However, the R2* values were not significantly different
between the two types of diabetic nephropathy in the
same renal compartment at the same time point (Table 4).
These results imply that the administration of 400 mg I/
mL of the contrast agent had similar effects on renal
oxygenation assessed by BOLD-MRI irrespective of. (A) Control group. (B) Type 2 diabetic nephropathy group injected
I/mL of contrast agent (C, 1 h; D, 24 h; E, 48 h; F, 72 h). Higher
ssue. The intensity of the outer medulla of the diabetic kidney was
genation of the outer medulla than the other regions.
Figure 3 Representative pathologic images. (A) Control group. (B) Type 2 diabetic nephropathy group injected with saline. (C–F) Type 2
diabetic nephropathy group injected with 400 mg I/mL of contrast agent (C, 1 h; D, 24 h; E, 48 h; F, 72 h). Changes in the glomerulus, renal
tubules, and interstitium can be easily seen at each time point in the type 2 diabetic nephropathy group following injection of the contrast
agent .
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type 2 diabetes.Image post-processing results
Using the coronary BOLD image of the left kidney in a
rabbit given 400 mg I/mL contrast agent as an example,
it is possible to see the renal cortex, outer medulla, and
inner medulla. The relative oxygenation status of the
kidney could be determined based on the staining inten-
sity on the R2* map. The area of high intensity in the
outer medulla of the diabetic kidney was larger than that
in the cortex and inner medulla, indicative of decreased
tissue oxygenation. The BOLD images obtained at each
time point are shown in Figure 2.Pathology and immunohistochemistry results
As shown in Figure 3, using the 400 mg I/mL group of
rabbits with experimentally induced type 2 diabetic ne-
phropathy, the glomerular structure is clearly visible,
without obvious atrophy shortly after injection. However,
the glomeruli (black arrows) gradually atrophy over
time and exhibit overt fibrosis at 72 h. The renal tubule
cells become turbid and enlarged, and show cavitation
changes at 24 h after contrast injection. Expansion and
congestion (blue arrow) of the capillaries is also appar-
ent and is followed by hemorrhage in the stroma. The
injury scores in the negative control group and the type
2 diabetic nephropathy group without contrast injection
were 0 and 0.08 ± 0.10, respectively. After injecting
400 mg I/mL contrast agent, the injury scores at 1, 24,
48, and 72 h were 0.29 ± 0.11, 0.64 ± 0.17, 0.60 ± 0.19,
and 0.56 ± 0.12, respectively. Table 5 compares the injuryTable 5 Pathological kidney injury scores after an
injection of 400 mg I/mL of contrast agent in the type 1
and type 2 diabetic nephropathy groups
1 h 24 h 48 h 72 h
Type 1 DN 0.29 ± 0.15 0.63 ± 0.24 0.60 ± 0.22 0.56 ± 0.21
Type 2 DN 0.29 ± 0.11 0.64 ± 0.17 0.60 ± 0.19 0.56 ± 0.12
Abbreviations: DN diabetic nephropathy.
Values are means ± standard deviation.
There were no significant differences in injury scores between the two groups
at the same times.scores between the type 1 and type 2 diabetic nephropa-
thy groups at each time.
Figure 4 shows that pimonidazole staining was mainly
localized to the renal outer medulla, and the renal cortex
was lightly stained. After injection of 400 mg I/mL of
the contrast agent, pimonidazole staining was weaker in
the cortex than in the outer medulla. The pimonidazole
staining scores in the cortex and outer medulla are
shown in Table 6.
Discussion
In this study of rabbit models of type 1 and type 2 dia-
betic nephropathy, we evaluated the renal blood oxygen-
ation levels of the renal cortex, outer medulla, and inner
medulla using BOLD-MRI after injecting contrast agents
containing different iodine concentrations. Using non-
invasive MRI, we assessed the effects of iodinated con-
trast agents containing different iodine concentrations
on the kidneys of rabbits with experimentally induced
diabetic nephropathy.
Under physiological conditions, renal oxygenation is low,
especially in the outer medulla [18,19]. Palm et al. [20] re-
ported that oxygen consumption of the renal medulla was
higher in the diabetic state because of an increase in meta-
bolic activity. Furthermore, it was reported that the kidney
of diabetic rats consumed about 40% more oxygen, mainly
because of the increased metabolic activity, compared with
nondiabetic rats [21]. Therefore, it was concluded that
hypoxia is associated with the development of diabetic ne-
phropathy despite adequately controlled glycemia [22].
Diabetic nephropathy is associated with high oxygen con-
sumption because of an increase in Na+-K+-ATP enzyme
activity and overloading of kidney tubules, especially those
in the proximal convoluted tubule and thick ascending
limb located in the outer medulla [20]. These events con-
tribute to further deteriorations in renal function [23,24].
In addition, glomerular hyperfiltration increases oxygen
consumption [25]. This was confirmed by our findings
that the R2* values were higher in the renal outer medulla
than in the other renal compartments in the type 2 dia-
betic nephropathy group, which indicates that oxygen
saturation is lower in the outer medulla than in other
compartments.
Figure 4 Representative immunohistochemistry images with pimonidazole staining. (A) Control group. (B) Type 2 diabetic nephropathy
group injected with saline. (C–F) Type 2 diabetic nephropathy group injected with 400 mg I/mL of contrast agent (C, 1 h; D, 24 h; E, 48 h;
F, 72 h). Pimonidazole staining was mainly localized in the renal outer medulla, especially at 24 h, while the renal cortex was lightly stained
following injection of 400 mg I/mL of contrast agent.
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nephrotoxicity by increasing the permeability of glomeru-
lar cells and prompting the apoptosis of tubular cells [26].
The viscosity of iodinated contrast agent causes a reduc-
tion in arterial oxygenation [27]. Viscous contrast agents
may also block small renal vessels [27]. The plasma viscos-
ity of iodinated contrast agents is also associated with re-
duced renal blood flow [28]. Decrease in renal perfusion
and/or increases in oxygen consumption contribute re-
duce the local oxygen saturation, especially in the renal
outer medulla [16]. In the present study, we assessed renal
oxygenation using BOLD-MRI. We found that R2* values
of the renal outer medulla were higher than those of the
renal cortex and inner medulla. These findings indicate
that the renal outer medulla has lower oxygenation satur-
ation and that iodinated contrast agents had greater effects
on oxygenation of the renal outer medulla than on other
renal components. This effect was greater in the 400 mg I/
mL group than in the other groups, and was probably due
to the higher iodine concentration and viscosity of the
contrast agent. Consequently, the differences in R2* values
might be attributable to the different iodine concen-
trations and the viscosities of the contrast agents. The
changes in glomerular structure and the renal tubules
were confirmed by pathology and the degree of hypoxia
was determined by pimonidazole staining.
In our study, BOLD-MRI was performed at 1, 24, 48,
and 72 h after injecting the iodinated contrast agents to
observe the changes in R2* values over time. We found
that the R2* values were higher after 1 h and reached
peaks at 24 h after injection. The R2* values declined
thereafter, reaching the lowest values at 72 h. TheseTable 6 Pimonidazole staining scores for the renal cortex and
contrast agent
CG Type 2 DN PC Type 2 DN at 1 h
Cortex 0.13 ± 0.01 0.53 ± 0.05 1.35 ± 0.12*
Outer medulla 0.12 ± 0.01 0.51 ± 0.06 1.87 ± 0.13*
Abbreviations: CG control group, DN diabetic nephropathy, PC positive control.
The CG and type 2 DN PC group were injected with physiological saline.
Values are means ± standard deviation.
*P < 0.05 vs. the cortex.
Pimonidazole staining scores were significantly different between the cortex and ou
the CG or the type 2 DN PC group.changes in R2* values suggest that the renal oxygenation
was lowest at 24 h. Furthermore, it seems that the renal
effects of the iodinated contrast agents were greatest at
24 h and gradually declined by 72 h after injection.
Nevertheless, the effects of the contrast agent persisted
for at least 72 h because the R2* values remained higher
than that in the control group.
To study the influence of injecting iodinated contrast
agents on the kidney in different types of diabetic ne-
phropathy, we examined the effects of 400 mg I/mL con-
trast agent in rabbit models of type 1 and type 2 diabetic
nephropathy and in control rabbits. The R2* values of both
diabetic nephropathy groups were significantly greater
than those of the control group. However, the R2* values
were not significantly different between the type 1 and
type 2 diabetic nephropathy groups. There are several
possible explanations for these findings. First, although the
etiologies of type 1 and type 2 diabetes differ, their effects
on the kidney and the reductions on oxygenation are not
significantly different [29-34]. Second, the study lasted
12 weeks, corresponding to an early stage of diabetic ne-
phropathy. Thus, the appearance of the difference might
be related to the severity of kidney damage at later stages
of diabetic nephropathy.
Limitations
First, type 1 diabetic nephropathy was established by an
injection of alloxan monohydrate, and type 2 diabetic
nephropathy was induced by a diet containing high
levels of fat and glucose. Thus, we established models of
diabetic nephropathy, which may not represent the true
pathogenesis of this disease. However, it should be notedouter medulla in rabbits injected with 400 mg I/mL of
Type 2 DN at 24 h Type 2 DN at 48 h Type 2 DN at 72 h
2.17 ± 0.17* 1.93 ± 0.08* 1.77 ± 0.14*
2.83 ± 0.11* 2.62 ± 0.12* 2.31 ± 0.09*
ter medulla at 1–72 h after injecting 400 mg I/mL of contrast agent, but not in
Wang et al. BMC Nephrology 2014, 15:140 Page 8 of 9
http://www.biomedcentral.com/1471-2369/15/140that the underlying pathogenesis of diabetic nephropathy
is still poorly understood and further studies are needed
in this field. Second, because the study lasted 12 weeks,
it is possible that differences between type 1 and type 2
diabetic nephropathy would have been more apparent if
we injected the iodinated contrast agents at a later stage
of diabetic nephropathy. This possibility must be exam-
ined in future studies.
Conclusions
This study revealed that the increases in R2* values were
greatest in the renal outer medulla at 24 h after injection of
iodinated contrast agents in a rabbit model of experimen-
tally induced type 2 diabetic nephropathy. These findings
indicated that renal oxygenation was lowest at 24 h after in-
jection, particularly in the renal outer medulla. Notably, the
highest dose of contrast agent tested (400 mg I/mL) had
the greatest effects on the kidneys. BOLD-MRI revealed
that the effects of this dose had similar effects on renal oxy-
genation in type 1 and type 2 diabetic nephropathy.
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